-
Mashup Score: 5Eisai Aims to Advance Genitourinary Cancer Treatment with New Research at ASCO GU 2024 - 4 month(s) ago
Data from the Pivotal Phase 3 CLEAR Trial and Phase 2 KEYNOTE-B61 Trial Provide Further Insight into the Role of Lenvatinib Plus Pembrolizumab as a First-Line Treatment Option for Patients with…
Source: media-us.eisai.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 6Eisai Furthers Oncology Research in Gastrointestinal Cancer Treatment with New Data at ASCO GI 2024 - 4 month(s) ago
Longer-Term Efficacy and Safety Results from the Phase 3 LEAP-002 Trial Offer Additional Information About the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma Data on…
Source: media-us.eisai.comCategories: General Medicine News, PayerTweet
#GU24 is just around the corner! Join us in San Francisco, CA, and virtually to discuss our latest data in genitourinary #cancer. We look forward to seeing you there! Read our press release to learn more: https://t.co/Wgd9Q7L3MM https://t.co/I4T5RzFBp4